ArriVent BioPharma, Inc.(AVBP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AVBP Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ArriVent BioPharma, Inc. (AVBP), a Healthcare sector company. AVBP is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), ArriVent BioPharma, Inc. reports net income of $-43.3M, free cash flow of $-41.9M. Top institutional holders of AVBP by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, INFINITUM ASSET MANAGEMENT,, Hillhouse Capital Advisors, Ltd., based on the most recent SEC filings. AVBP trades on the Nasdaq exchange and files with the SEC under CIK 1868279. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVBP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ArriVent BioPharma, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-43.3M
Free Cash Flow
Q1 2026
$-41.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-106.6% YoYOperating Income
-88.2% YoYEPS (Diluted)
-68.8% YoYTotal Assets
+21.2% YoYOp. Cash Flow
-128.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net Income | $-166.3M -106.6% | $-80.5M -16.1% | $-69.3M | — |
| Operating Income | $-177.5M -88.2% | $-94.3M -26.4% | $-74.6M | — |
| EPS (Diluted) | $-4.32 -68.8% | $-2.56 -20.2% | $-2.13 | — |
| Total Assets | $333.2M +21.2% | $274.9M +68.6% | $163.1M | — |
| Operating Cash Flow | $-160.6M -128.7% | $-70.2M -25.7% | $-55.8M | — |
Get alerted when AVBP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ArriVent BioPharma, Inc. including:
Top Institutional Holders of AVBP
SUVRETTA CAPITAL MANAGEMENT, LLC
$101.5M4,401,083 shINFINITUM ASSET MANAGEMENT, LLC
$95.7M4,148,923 shHillhouse Capital Advisors, Ltd.
$90.6M3,929,117 shORBIMED ADVISORS LLC
$69.8M3,027,328 shFMR LLC
$69.6M3,016,132 shBlackRock, Inc.
$58.4M2,530,301 shOctagon Capital Advisors LP
$45.5M1,971,054 shNovo Holdings A/S
$44.8M1,942,142 shSofinnova Ventures Inc
$39.1M1,696,752 shVANGUARD CAPITAL MANAGEMENT LLC
$35.3M1,528,893 sh
| Fund | Value | Shares |
|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | $101.5M | 4,401,083 |
| INFINITUM ASSET MANAGEMENT, LLC | $95.7M | 4,148,923 |
| Hillhouse Capital Advisors, Ltd. | $90.6M | 3,929,117 |
| ORBIMED ADVISORS LLC | $69.8M | 3,027,328 |
| FMR LLC | $69.6M | 3,016,132 |
| BlackRock, Inc. | $58.4M | 2,530,301 |
| Octagon Capital Advisors LP | $45.5M | 1,971,054 |
| Novo Holdings A/S | $44.8M | 1,942,142 |
| Sofinnova Ventures Inc | $39.1M | 1,696,752 |
| VANGUARD CAPITAL MANAGEMENT LLC | $35.3M | 1,528,893 |
More Healthcare Companies
View all Healthcare →Put AVBP on your watchlist
Track score changes the day ArriVent BioPharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AVBP a good stock to buy?
13F Pro's AI-powered analysis of ArriVent BioPharma, Inc. (AVBP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVBP are available on the AVBP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AVBP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVBP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ArriVent BioPharma, Inc.'s investment landscape.